Cortechs.ai | The importance of quantitative volumetric analysis

The importance of quantitative volumetric analysis

For over 20 years, volumetric MR imaging (vMRI) technology has been available in research and clinical environments.Initially, radiology centers developed and used their own imaging parameters and manually evaluated the resulting images. This made clinical application subjective, inconsistent from patient to patient and from scanner to scanner,and all but impractical. The introduction of large-scale multi-institutional research studies, such as ADNI (Alzheimer’s Disease Neuroimaging Initiative) in 2004, initiated the streamlining and standardizing of acquisition protocols. In 2006, CorTechs Labs introduced NeuroQuant, the first FDA cleared automated segmentation software, which provided consistent, operator independent measurements of brain structure volumes. Together, these factors permitted clinical users to easily incorporate volumetric MRI technology into their clinical practice.


More Resources

09/03/2025

Reimbursement Considerations for OnQ Prostate and Category III CPT Codes 0648T & 0649T

Learn how Cat. III CPT codes 0648T and 0649T apply to OnQ™ Prostate, offering guidance for accurate reporting, reimbursement, and building evidence for coverage

09/02/2025

Maximizing the Value of Prostate MRI for the Urologist

Even with expert radiologists or AI models at hand, the challenge remains: how can urologists improve seeing and interpreting cancer?

08/18/2025

Why Bigger Normative Databases Mean Better Brain Imaging

NeuroQuant® 5.2 compares patient brain MRI volumes to over 7,000 healthy scans, giving clinicians clear, percentile-based context for better assessments.

08/07/2025

Navigating Reimbursement for NeuroQuant: Understanding CPT Codes 0865T & 0866T 

Let’s break down the latest category III CPT codes and example clinical use cases that illustrate their value.

07/31/2025

Precision Without the Pressure: Smarter Brain Tumor Monitoring

Learn about NeuroQuant Brain Tumor 2.0 and how it assists clinicians by providing objective quantification and analysis of tumor changes over time.

07/30/2025

Cortechs.ai Announce Next-Gen NeuroQuant Brain Tumor: AI-Driven Metastasis & Meningioma Segmentation 

NeuroQuant Brain Tumor is the first FDA-cleared, cloud-native tool to offer automated volumetric segmentation for brain metastases, meningiomas, and gliomas.
Scroll to Top